AVEO Pharmaceuticals, Inc. Short Interest Up 98.9% in July!
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was the target of a large increase in short interest in the month of July. As of July 14th, there was short interest totalling 7,275,061 shares, an increase of 98.9% from the June 30th total of 3,657,353 shares. Currently, 8.4% of the company’s stock are short sold. Based on an average daily volume of 8,475,366 shares, the days-to-cover ratio is presently 0.9 days. A number of large investors have recently modified their holdings of AVEO. Paloma Partners Management Co purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $184,000. Clear Harbor Asset Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter valued at $289,000. UBS Oconnor LLC purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $291,000. Sabby Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the first quarter valued at $513,000. Finally, Renaissance Technologies LLC boosted its stake in shares of AVEO Pharmaceuticals by 5.7% in the fourth quarter. Renaissance Technologies LLC now owns 2,743,900 shares of the biopharmaceutical company’s stock valued at $1,482,000 after buying an additional 148,500 shares during the last quarter. 50.96% of the stock is currently owned by institutional investors.
Several analysts recently issued reports on AVEO shares. FBR & Co reissued a “buy” rating on shares of AVEO Pharmaceuticals in a research report on Saturday, April 8th. Piper Jaffray Companies set a $2.00 price target on shares of AVEO Pharmaceuticals and gave the company a “buy” rating in a research report on Saturday, June 24th. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Monday. Finally, ValuEngine raised shares of AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 24th.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 2.45 on Thursday. The firm’s market cap is $270.39 million. AVEO Pharmaceuticals has a 52-week low of $0.50 and a 52-week high of $3.19. The company has a 50-day moving average of $1.85 and a 200 day moving average of $0.98. AVEO Pharmaceuticals (NASDAQ:AVEO) last issued its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). The company had revenue of $2.53 million for the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 728.85%. On average, equities analysts expect that AVEO Pharmaceuticals will post ($0.39) earnings per share for the current year. About AVEO Pharmaceuticals AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
